Mark Petersen | Senior Scientist
Zymeworks

Mark Petersen is a senior scientist in the medical chemistry in ADC therapeutic development group at Zymeworks, where he is has contributed to and lead the development of multiple cytotoxic ADC platforms.  Prior to joining Zymeworks in 2017, Mark studied natural product synthesis in the lab of Prof. Gary Keck at the University of Utah followed by a NIH postdoctoral fellowship with Prof. Michael Kay focusing on chemical protein synthesis and peptide drug discovery.